CMPS

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Jul 08, 9:45 PMEvercore ISI upgrades Compass Pathways to Outperform, raises price target to $21 on positive COMP360 Phase 3 data

Peers: AXSM NBIX RYTM KYMR NUVL BMRN KRYS VKTX MDGL NUTX

| Held by: ARKG IBB PSIL SBIO SURI GWX AADR HTEC BBC APIE

Scroll to Statements

Index	-
Market Cap	1.83B
Enterprise Value	1.42B
Income	-191.97M
Sales	0.00M
Book/sh	2.42
Cash/sh	3.46
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	156
IPO	Sep 18, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	5.62
P/C	3.93
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.32
Current Ratio	3.32
Debt/Eq	0.16
LT Debt/Eq	0.16
Option/Short	Yes / Yes

EPS (ttm)	-3.16
EPS next Y	-1.39
EPS next Q	-0.39
EPS this Y	74.37%
EPS next Y	-75.93%
EPS next 5Y	56.76%
EPS past 3/5Y	-12.71% -12.77%
Sales past 3/5Y	- -
EPS Y/Y TTM	-9.94%
Sales Y/Y TTM	-
EPS Q/Q	-51.37%
Sales Q/Q	-
Earnings	May 13 BMO
EPS/Sales Surpr.	261.66% -

Insider Own	4.58%
Insider Trans	0.00%
Inst Own	66.05%
Inst Trans	32.68%
ROA	-45.12%
ROE	-73.53%
ROIC	-50.79%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	5.40%
SMA50	16.41%
SMA200	75.62%
Trades

Shs Outstand	134.92M
Shs Float	128.74M
Short Float	6.49%
Short Ratio	1.75
Short Interest	8.36M
52W High	15.40 -11.69%
52W Low	3.45 294.20%
Volatility	9.48% 8.17%
ATR (14)	1.04
RSI (14)	56.18
Beta	2.50
Rel Volume	0.64
Avg Volume	4.77M
Volume	3,023,427

Perf Week	2.33%
Perf Month	15.94%
Perf Quarter	137.76%
Perf Half Y	92.91%
Perf YTD	97.10%
Perf Year	285.27%
Perf 3Y	37.65%
Perf 5Y	-62.89%
Perf 10Y	-
Recom	1.00
Target Price	23.44
Prev Close	13.97
Price	13.60
Change	-2.61%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-08-26	Upgrade	Evercore ISI	In-line → Outperform	$21
May-22-26	Initiated	Wolfe Research	Outperform
May-04-26	Initiated	Jefferies	Buy	$18
Apr-24-26	Initiated	B. Riley Securities	Buy	$17
Dec-10-25	Upgrade	Oppenheimer	Perform → Outperform	$15
Jun-23-25	Downgrade	Evercore ISI	Outperform → In-line	$11 → $6
Feb-27-25	Initiated	Stifel	Buy	$11
Jul-23-24	Initiated	RBC Capital Mkts	Outperform	$23
Apr-01-24	Initiated	Morgan Stanley	Overweight	$30
Dec-12-23	Initiated	Deutsche Bank	Buy	$16
Nov-21-22	Resumed	Berenberg	Buy	$33
Nov-01-22	Initiated	Loop Capital	Buy	$34
Oct-29-21	Initiated	Oppenheimer	Outperform	$50
Jul-13-21	Initiated	Citigroup	Buy	$67
Jun-28-21	Initiated	Maxim Group	Buy	$70
May-11-21	Initiated	Cantor Fitzgerald	Overweight	$71
Apr-01-21	Initiated	ROTH Capital	Buy	$88
Oct-14-20	Initiated	H.C. Wainwright	Buy	$65
Oct-13-20	Initiated	Evercore ISI	Outperform
Oct-13-20	Initiated	Cowen	Outperform

Show Previous Ratings

Jul-08-26 09:28PM	CMPS Stock Climbs After-Hours: Analyst Sees Depression Drug Approval By H1 2027 Or Sooner After Strong Trial Data (Stocktwits) +7.51%
Jul-07-26 06:13PM	CMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drugs Durability Ahead Of FDA Filing (Stocktwits)
09:49AM	Why Psychedelics-Tied Compass Pathways Isn't Getting High (Investor's Business Daily)
08:15AM	Compass Pathways Clears Another Hurdle Builds Stronger FDA Case For Its Much-Awaited Depression Therapy (Stocktwits)
06:30AM	Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile (Business Wire)
06:30AM	Loading…
Jul-02-26 06:30AM	Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-26-26 09:30AM	A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year (PR Newswire) +9.13%
Jun-24-26 07:00AM	3 Companies Redefining Healthcare Innovation (ETF Trends)
06:56AM	To Wall Street, psychedelics biotechs are more teammates than rivals (BioPharma Dive)
Jun-05-26 06:30AM	Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.20%
May-28-26 06:30AM	Compass Pathways Elects Kathleen Tregoning to Board of Directors (Business Wire)
May-26-26 06:30AM	Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026 (Business Wire)
May-18-26 10:08AM	This Psychedelics Stock Just Keeps Getting Hotter; Why Shares Bypassed A Profit-Taking Zone (Investor's Business Daily)
May-14-26 06:30AM	Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026 (Business Wire)
May-13-26 07:02PM	Compass Pathways PLC (CMPS) Q1 2026 Earnings Call Highlights: Promising Advances in ... (GuruFocus.com) +16.97%
12:39PM	Loading…
12:39PM	Here's Why This Psychedelics Stock Just Took A Trip To A Two-Year High (Investor's Business Daily)
12:33PM	Compass Pathways shares rise on Q1 results, accelerated FDA review (Proactive)
08:54AM	Compass Pathways jumps after earnings beat and accelerated FDA review progress (CMPS) (InvestorsHub)
07:48AM	Nasdaq continues to gain but Dow still red as Trump arrives in China (Proactive)
06:30AM	Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights (Business Wire)
May-06-26 06:30AM	Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026 (Business Wire)
06:25AM	Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-27-26 09:16AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) -7.20%
Apr-24-26 03:59PM	FDA Fast-Tracks Review of Some Psychedelic Drugs. This Stock Is Set to Benefit. (Barrons.com)
11:58AM	Psychedelic Pharma Stocks Are Riding High. Past Cannabis Returns Are a Reality Check. (Barrons.com)
10:37AM	Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher (Business Wire)
Apr-22-26 08:49AM	Can I have some, please?: Trump jokes as he signs psychedelics order after Joe Rogan push. These stocks soar (Moneywise) -5.41%
Apr-21-26 06:30AM	Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments (Business Wire)
Apr-20-26 02:34PM	Market Feels Weak, But Stocks Tell Stories (GuruFocus.com) +42.04%
12:41PM	Trump Signs Psychedelic Drugs Order. 4 Stocks That Are Surging. (Barrons.com)
11:48AM	Loading…
11:48AM	Trump Pushes for Speedy Psychedelic Approvals, Sending Stocks Surging (The Wall Street Journal)
10:01AM	How Trump Sent Psychedelics-Tied Compass Pathways And Others Flying (Investor's Business Daily)
08:26AM	Psychedelic stocks rally with Trump's support (MarketWatch)
08:18AM	Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring. (Barrons.com)
06:30AM	Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026 (Business Wire)
05:53AM	Psychedelic stocks soar after Trump signs executive order to fast-track treatments (Investing.com)
Apr-18-26 04:12PM	Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments (Business Wire)
Apr-17-26 04:00AM	Can an LSD candidate do for anxiety what Spravato did for depression? (Pharma Voice)
Apr-14-26 06:30AM	Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training (Business Wire)
Apr-08-26 06:30AM	Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026 (Business Wire)
Apr-07-26 04:30PM	Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-29-26 10:25AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Mar-24-26 07:30AM	Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights (Business Wire)
Mar-12-26 06:30AM	Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026 (Business Wire)
Mar-10-26 07:30AM	Cathie Wood Bets $19 Million on 5 Beaten-Down Stocks (Barchart) +8.45%
Mar-09-26 10:50AM	CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions (PR Newswire)
Mar-08-26 02:03PM	Compass Pathways Highlights Phase 3 COMP360 TRD Gains, 26-Week Durability and FDA Path at Conference (MarketBeat)
Feb-26-26 12:07PM	Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders (PR Newswire)
06:30AM	Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants (Business Wire)
Feb-24-26 09:35AM	Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity (PR Newswire)
06:39AM	Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026 (Business Wire)
Feb-23-26 03:00AM	How does the FDA really feel about psychedelics? We could soon find out. (Pharma Voice)
Feb-22-26 07:43PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Feb-20-26 11:14AM	Magic Mushrooms, Hard Cash: Compass Pathways' Trial Win, Fast Raise (MarketBeat)
10:01AM	Cathie Wood Pours $24 Million to This AI Software Stock (GuruFocus.com)
09:40AM	Are Medical Stocks Lagging Auna S.A. (AUNA) This Year? (Zacks)
Feb-19-26 11:40AM	The FDA could approve key component of magic mushrooms as a depression treatment (Quartz)
11:38AM	FDA could approve magic mushroom chemical for depression (Quartz)
Feb-18-26 09:31PM	Analysts Bullish on COMPASS Pathways plc (CMPS) Following Psychedelics Symposium and Model Updates (Insider Monkey) +10.75%
08:18PM	Compass Pathways Announces Pricing of $150 Million Public Offering (Business Wire)
08:01AM	Compass stock heads north on psychedelics Phase III TRD success (Clinical Trials Arena)
04:25AM	Psychedelics stocks rise as Compass psilocybin drug heads to FDA (BioPharma Dive)
Feb-17-26 04:06PM	Compass Pathways Launches Proposed $150.0 Million Public Offering (Business Wire) +31.33%
02:59PM	COMPASS Pathways touts Phase III psilocybin wins in TRD, eyes FDA NDA and expedited review (MarketBeat)
09:12AM	COMPASS Pathways Triumph In Hard To Treat Depression Ignites Investor Frenzy (Benzinga)
06:53AM	Compass, with Phase 3 hits, ready to take psilocybin to the FDA (BioPharma Dive)
06:30AM	Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression (Business Wire)
Feb-16-26 08:00AM	Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials (Business Wire)
Jan-07-26 06:30AM	Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD (Business Wire) +10.92%
Jan-06-26 06:30AM	Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360 (Business Wire) +7.47%
Dec-27-25 07:43AM	Why COMPASS Pathways plc (CMPS) Draws Both Optimism and Caution (Insider Monkey)
Dec-09-25 06:30AM	Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET (Business Wire)
Dec-04-25 04:07PM	Compass Pathways Eyes FDA Approval for Psilocybin Depression Drug (Bloomberg) +11.59%
Nov-20-25 06:30AM	Compass Pathways to Participate in Two Investor Conferences in December (Business Wire)
Nov-05-25 06:30AM	Compass Pathways to Participate in Stifel 2025 Healthcare Conference (Business Wire) -17.19%
Nov-04-25 04:03PM	Compass Pathways PLC (CMPS) Q3 2025 Earnings Call Highlights: Accelerated Launch Plans and ... (GuruFocus.com) +11.43%
06:30AM	Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months (Business Wire)
Nov-02-25 04:32PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Oct-30-25 08:30AM	NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression (PR Newswire)
Oct-29-25 06:30AM	Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors (Business Wire)
Oct-28-25 06:30AM	Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025 (Business Wire)
Oct-07-25 01:19AM	As setbacks plague other companies, MindMed becomes a front-runner in the psychedelics race (Pharma Voice)
Sep-07-25 05:29PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Sep-02-25 06:30AM	Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder (Business Wire)
03:47AM	COMPASS Pathways Plc (CMPS)' Psilocybin Therapy Hits Phase 3 Success in Depression (Insider Monkey)
Aug-27-25 06:30AM	Compass Pathways to Participate in Four Investor Conferences in September (Business Wire)
Aug-25-25 07:50AM	AbbVie wagers more than $1B on Gilgameshs psychedelic drug (BioPharma Dive)
Aug-05-25 11:55AM	Compass Pathways price target lowered to $40 from $45 at H.C. Wainwright (TipRanks)
06:30AM	Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA (Business Wire)
Aug-01-25 05:01AM	Compass Pathways PLC (CMPS) Q2 2025 Earnings Call Highlights: Clinical Success and Strategic ... (GuruFocus.com)
Jul-31-25 06:30AM	Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights (Business Wire) +10.41%
Jul-29-25 06:30AM	Compass Pathways Appoints Justin Gover to Board of Directors (Business Wire)
Jul-22-25 06:30AM	Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025 (Business Wire)
Jul-20-25 04:48AM	These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy? (Motley Fool)
Jul-15-25 04:58PM	Cathie Wood's ARK Adds 125K COMPASS Pathways plc (CMPS) Shares (Insider Monkey) +10.39%
Jul-10-25 04:00PM	Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET (Business Wire) +5.38%
Jul-08-25 12:00PM	COMPASS Pathways (CMPS) Upgraded to Buy: Here's Why (Zacks)
Jun-29-25 06:01PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
07:00AM	This Psychedelic Drug Flopped on Trial Results. Should You Buy the Dip? (Barchart)
Jun-27-25 11:50AM	Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial (TipRanks)

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

M.B.A.Mr. Kabir Kumar Nath M.A.

Chief Financial OfficerMs. Teri Loxam M.B.A.

Chief Medical OfficerDr. Guy Goodwin

Senior Vice President of Investor RelationsMr. Stephen D. Schultz

Senior AdvisorMr. Lars Christian Wilde

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Compass Pathways Plc ADR

Upgrade your Finviz experience